This article is more than 5 years old. Information may no longer be current.

Eliquis approved in Europe for treatment of DVT, PE

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bristol-Myers Squibb and Pfizer announced that apixaban, a novel oral anticoagulant, has been approved by the European Commission for the treatment of deep vein thrombosis and pulmonary embolism and the prevention of recurrent DVT and PE in adults.

The approval covers all countries in the European Union, as well as Iceland and Norway, according to a press release from the companies.

Apixaban (Eliquis) had previously been approved in Europe for the prevention of venous thromboembolism in adults who underwent total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation and at least one other risk factor.

“Every year, approximately one million patients in the EU are diagnosed with VTE,” Elliott Levy, MD, senior vice president and head of specialty development for Bristol-Myers Squibb, said in the release. “Once a VTE has occurred, approximately 33% of patients may experience a recurrence in 10 years.”